Hematología y Hemoterapia

Resultados: 466
Tipo Título / Nombre Autor(es) Año
Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study Barragán E, Gil JV, Ayala R, Chillón C..., Bergua J 2026
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial Vitolo U, Burgues JMB, Duell J, Kwiatek M, Belada D, Jurczak W, et al 2026
Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies Vallejo C, González C, Gaya A, de la Iglesia S..., Carnicero F 2026
Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study Gil JV, Sargas C, Ayala R, Gutierrez NC..., Bergua Burgues JM 2026
Beta-Thalassemia in Spain: Results From the National Thalassemia Registry and Molecular Analysis of Patients With Transfusion-Dependent Thalassemia Villegas A, Ropero P, González FA, Morado M..., Ugalde N 2026
Fosfomycin versus ciprofloxacin for febrile neutropenia prophylaxis in high-risk haematological patients (FOVOCIP): a phase 3, open-label, multicentre, randomised, non-inferiority trial Moreno AF, López de Ugarriza P, González Huerta AJ..., Cáceres S, Izquierdo M 2026
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group Colmenares R, Barragán E, Rodríguez-Veiga R, Torres-Miñana L..., Bergua J 2026
Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia Ribera JM, Torrent A, Morgades M..., Bergua Burgues JM 2026
Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study Aspas Requena G, Rodríguez-Veiga R, Gil C, Botella C, Aguiar E..., Bergua Burgues JM, et al 2026
Desaparición espontánea de un inhibidor bajo tratamiento con Emicizumab en un paciente con Hemofilia A leve Domínguez Mora AR, Bermejo Vega N, Calzadilla Román KS, Casado Cabanillas V, Macías Maeso J, Román Molano LG, et al 2026